3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
257
Neoplasms
225
Carcinoma, Non-Small-Cell Lung
206
Colorectal Neoplasms
148
Prostatic Neoplasms
142
Lung Neoplasms
116
Neoplasm Metastasis
106
Ovarian Neoplasms
103
Multiple Myeloma
98
Pancreatic Neoplasms
89
Leukemia, Myeloid, Acute
79
Squamous Cell Carcinoma of Head and Neck
75
Endometrial Neoplasms
65
Melanoma
64
Stomach Neoplasms
60
Recurrence
59
Glioblastoma
57
Brain Neoplasms
56
Urinary Bladder Neoplasms
51
Carcinoma, Hepatocellular
51
Triple Negative Breast Neoplasms
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
49
Lymphoma
48
Head and Neck Neoplasms
47
Carcinoma, Renal Cell
46
Hematologic Neoplasms
44
Esophageal Neoplasms
43
Colonic Neoplasms
43
Uterine Cervical Neoplasms
42
Glioma
42
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Camurati-Engelmann Syndrome
×
30 days
×
Clear all
NCT06788990
2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3
Recruiting
650 enrolled
NCT05209776
2026-06-01
LI-ARVC
University Hospital, Toulouse
Phase NA
Recruiting
80 enrolled